ZA200209815B - Aromatase inhibitors and monoclonal anti-HER2 antibodies as antitumors agents. - Google Patents
Aromatase inhibitors and monoclonal anti-HER2 antibodies as antitumors agents. Download PDFInfo
- Publication number
- ZA200209815B ZA200209815B ZA200209815A ZA200209815A ZA200209815B ZA 200209815 B ZA200209815 B ZA 200209815B ZA 200209815 A ZA200209815 A ZA 200209815A ZA 200209815 A ZA200209815 A ZA 200209815A ZA 200209815 B ZA200209815 B ZA 200209815B
- Authority
- ZA
- South Africa
- Prior art keywords
- her2
- aromatase inhibitor
- antibody against
- human
- exemestane
- Prior art date
Links
- 239000003886 aromatase inhibitor Substances 0.000 title claims description 40
- 230000000259 anti-tumor effect Effects 0.000 title claims description 12
- 229940046844 aromatase inhibitors Drugs 0.000 title description 7
- 239000003795 chemical substances by application Substances 0.000 title description 2
- 229940122815 Aromatase inhibitor Drugs 0.000 claims description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 230000001419 dependent effect Effects 0.000 claims description 17
- 229940088597 hormone Drugs 0.000 claims description 16
- 239000005556 hormone Substances 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 230000002018 overexpression Effects 0.000 claims description 13
- 229960000255 exemestane Drugs 0.000 claims description 12
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 230000002195 synergetic effect Effects 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 229960002932 anastrozole Drugs 0.000 claims description 8
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 8
- 229960000575 trastuzumab Drugs 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- -1 roglethimide Chemical compound 0.000 claims description 5
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 201000009273 Endometriosis Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 229950011548 fadrozole Drugs 0.000 claims description 4
- 229960004421 formestane Drugs 0.000 claims description 4
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims description 4
- 230000002611 ovarian Effects 0.000 claims description 4
- 229960003437 aminoglutethimide Drugs 0.000 claims description 3
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims description 3
- PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 claims description 3
- 229950004810 atamestane Drugs 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- QXKJWHWUDVQATH-UHFFFAOYSA-N rogletimide Chemical compound C=1C=NC=CC=1C1(CC)CCC(=O)NC1=O QXKJWHWUDVQATH-UHFFFAOYSA-N 0.000 claims description 3
- 229960005353 testolactone Drugs 0.000 claims description 3
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 claims description 3
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 claims description 3
- 229960001670 trilostane Drugs 0.000 claims description 3
- 229960001771 vorozole Drugs 0.000 claims description 3
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 13
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 13
- 208000035475 disorder Diseases 0.000 description 15
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 229960003881 letrozole Drugs 0.000 description 3
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents
The present invention concerns the treatment of hormone dependent disorders characterized by the overexpression of
HER2. More specifically, the invention concerns the treatment of a human being susceptible to or diagnosed with a disorder characterized by the overexpression of
HER2 with a combination of an anti-HER2 antibody and an aromatase inhibitor.
Proto-oncogens that encode growth factors and growth factors receptors have been identified to play important roles in the pathogenesis of various malignancies, including breast cancer. In particular numerous studies have demonstrated the prognostic relevance of pl85 (HER2), which is overexpressed in 10% to 40% of human breast tumors. Moreover a recombinant humanized anti-HER2 monoclonal antibody (a humanized version of the murine anti-HER-2 antibody 4DS5, referred to as Herceptin®) has been found clinically active in patients with HER2- overexpressing breast cancer (J. Clin. Oncol. 14:737-744, 1996). Also the utility of aromatase inhibitors is well acknowledged in anticancer therapy. However, it is also well known in the art that administration to a patient of therapeutically effective amounts of aromatase inhibitors can cause considerable side effects. The major toxicities are for instance lethargy, hot flashes, rash, transient leukopenia, dizzines, nausea, constipation and vomiting.
On the other hand, also administration to a patient of therapeutically effective amounts of an antibody against
HER2 can similarly cause considerable side effects, e.g. hypersensitivity, alterations of renal function, myocardial lesions and cardiotoxicity in general.
SUBSTITUTE SHEET (RULE 26)
The inventors of the present invention have found that a combination therapy of an hormone dependent disorder characterized by the overexpression of HER2, comprising a therapeutically effective amount of an aromatase inhibitor and a therapeutically effective amount of an antibody against HER2, can produce a therapeutic effect which is greater than that obtainable by single administration of a therapeutically effective amount of either a sole aromatase inhibitor or a sole antibody against HER2.
Similarly they have found that a combination therapy of an hormone dependent disorder characterized by the overexpression of HER2, comprising a therapeutically sub- effective amount of an aromatase inhibitor and a therapeutically sub-effective amount of an antibody against HER2, can produce substantially the same therapeutic effect, which is obtainable by single administration of a therapeutically effective amount of either an aromatase inhibitor or an antibody against HER2.
The most important, they have found that such newly obtained therapeutic effect is not paralleled by the toxic effects, otherwise caused by single administrations of either therapeutically effective amounts of an aromatase inhibitor or therapeutically effective amounts of an anti-
HER2 antibody.
In view of the above, the effectiveness of an aromatase inhibitor and an antibody against HER2 is significantly increased without a parallel increased toxicity. In other words, the combined therapy of the present invention enhances the therapeutic effects of the aromatase inhibitor and the antibody against HER2 and thus yields more effective and less toxic treatment for ~hormone- dependent disorders.
Accordingly, the present invention provides a new and valuable tool in the therapy of hormone dependent
SUBSTITUTE SHEET (RULE 26)
disorders characterized by the overexpression of HER2. The advantages provided by the present invention can be appreciated by their preferred features, described herebelow.
Examples of such disorders are cancers, e.g. breast, cervical, ovarian and endometrial cancers, and endometriosis. However such disorder is preferably breast cancer in a human being, in particular a female.
Accordingly, the present invention provides, as a first object, a pharmaceutical composition comprising an aromatase inhibitor and an antibody against HER2, having a synergistic or superadditive therapeutic activity against an hormone-dependent disorder characterized by the overexpression of HER2.
The present invention also provides the use of an aromatase inhibitor in the manufacture of a pharmaceutical composition for treatment of an hormone-dependent disorder characterized by the overexpression of HER2, the treatment additionally comprising the administration of a composition comprising an antibody against HER2, in amounts effective to produce a superadditive effect.
Examples of aromatase inhibitors according to the invention are exemestane, aminoglutethimide, roglethimide, pyridoglutethimide, anastrazole, trilostane, testolactone, formestane, atamestane, 1l-methyl-1,4-androstadiene-3,17- dione (MAD), ketokonazole, fadrozole, letrozole, vorozole and anastrozole.
Preferred examples of aromatase inhibitors according to the invention are exemestane, anastrozole and letrozole, in particular exemestane.
SUBSTITUTE SHEET (RULE 26)
The aromatase inhibitors cited herein are well known products, which are cited for instance in Cancer-Treat-
Res.: 94, 231-254, 1998 and WO 99/30708.
Unless otherwise indicated, the terms “HER2” and ErbB2” when used herein refer to the human protein and are used interchangeably.
An antibody against HER2, according to the invention, can be either and “intact” antibody or a fragment thereof.
The term “antibody” is used in the broadest sense and specifically covers intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g. bispecific antibodies) formed from at least two intact antibodies, and antibody fragments so long as they exhibit the desired biological activity. “Antibody fragments” comprise a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody.
Examples of antibody fragments include Fab, Fab’, F(ab’)2, and Fv fragments; diabodies; linear antibodies; single- chain antbody molecules; and multispecific antibodies formed from antibody fragments.
A preferred example of an antibody against HER2 is trastuzumab.
The recombinant humanized monoclonal antibody anti-HER2 trastuzumab (Herceptin®) is described in various scientific publications, for example Cancer Res., 1998, 58: 2825-2831. .
The present invention also provides a product comprising an aromatase inhibitor and an antibody against HER2, as combined preparation for simultaneous, separate or sequential administration, in amounts to produce a synergistic or superadditive therapeutic activity against an hormone-dependent disorder characterized by the overexpression of HER2. :
SUBSTITUTE SHEET (RULE 26)
In a further aspect, the present invention provides a kit - comprising, in a suitable container means, a pharmaceutical composition containing an aromatase inhibitor, as an active agent, and an antibody against 5 HER2, as a further active agent, in amounts to produce a synergistic or superadditive therapeutic activity against hormone-dependent disorder characterized by the overexpression of HER2.
A further aspect of the present invention is to provide a method of treating a human being, particularly a female, suffering from an hormone-dependent disorder characterized by the overexpression of HER2 comprising administering to said human being an aromatase inhibitor and an antibody against HER2, in amounts effective to produce a superadditive or synergistic therapeutic effect.
A still further aspect of the present invention is to provide a method for lowering the side effects (adverse reactions) caused by antitumor therapy with an aromatase inhibitor in a human being, particularly a female, suffering from an hormone-dependent tumor overexpressing
HER2, the method comprising administering to said human being a combined preparation comprising an aromatase inhibitor and an antibody against HER2, in amounts effective to produce a superadditive or synergistic antitumor effect.
A still further aspect of the present invention is to provide a method for lowering the side effects (adverse reactions) caused by antitumor therapy with an antibody against HER2 in a human being, particularly a female, suffering from an hormone-dependent tumor overexpressing
HER2, the method comprising administering to said human being a combined preparation comprising an antibody
SUBSTITUTE SHEET (RULE 26)
against HER2 and an aromatase inhibitor, in amounts effective to produce a superadditive or synergistic antitumor effect.
By the term “a superadditive or synergistic antitumor ~~ effect” as used herein is meant the inhibition of the growth tumor, preferably the complete regression of the tumor, by administering a combination of an aromatase inhibitor, as defined above, and an antibody against a
HER2, to a human being, particularly a human female.
Said preparation having therefore a potentiated antitumor (superadditive) activity with respect to products containing either an aromatase inhibitor or an antibody against HER2.
By the term “administered" or “administering” as used herein is meant any acceptable manner of ‘administering a drug to a patient which is medically acceptable including parenteral and oral administration.
By “parenteral” is meant intravenous, subcutaneous, intradermal or intramuscular administration.
Oral administration includes administering the costituents of the combined preparation in a suitable oral form such as, e.g., tablets, capsules, suspensions, solutions, emulsions, powders, syrups and the like.
Parenteral administration includes administering the constituents of the combined preparation by subcutaneous, subcutaneous, intravenous or intramuscular injections.
The actual preferred method and order of administration of the combined preparations of the invention may vary according to, inter alia, the particular pharmaceutical formulation of the aromatase inhibitor being utilized, the particular pharmaceutical formulation of the antibody against the growth factor receptor being utilized, the particular cancer being treated and the particular patient
SUBSTITUTE SHEET (RULE 26)
being treated.
The dosage ranges for the administration of the combined preparation may vary with the age, condition and extent of the disease in the patient and can be determined by one of skill in the art.
The dosage regimen must therefore be tailored to the particular of the patient's conditions, response and associate treatments in a manner which is conventional for any therapy, and may need to be adjusted in response to changes in conditions and/or in light of other clinical conditions.
In the combined method of treatment according to the subject invention, the aromatase inhibitor may be administered simultaneously with the antibody against HER?2 or the compounds may be administered sequentially, in either order. - An effective amount of an aromatase inhibitor antitumor agent may vary from about 0.5 to about 500 mg pro dose 1-2 ’ times a day. Exemestane, for example, may be administered orally in a dosage range varying from about 5 to about 200 mg, and particularly, from about 10 to about 25 mg, or parenterally from about 50 to about 500 mg, in particular from about 100 to about 250 mg.
Fadrozole, for example, may be administered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2 mg.
Letrozole, for example, may be administered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2.5 mg.
Formestane, for example, may be administered parenterally in a dosage range varying from about 250 to about 500 mg, and particularly, from about 250 to about 300 mg.
Anastrozole, for example, may be administered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2 mg.
SUBSTITUTE SHEET (RULE 26)
In the method of the subject invention, for example for the administration of the recombinant humanized monoclonal antibody anti-HER2 trastuzumab, the course of therapy generally employed is from about 1 to about 1000 mg/m? of body surface area. More preferably, the course therapy employed is from about 50 to about 500 mg/m? of body surface area.
The therapy method according to the present invention is, in particular, suitable for treating a human being suffering from hormone dependent disorders, characterized by the overexpression of HER2. Typical examples of such disorders are endometriosis and tumors, like ovarian, cervical and endometrial cancers in a human female or breast cancer in a human being, in particular a female.
More in particular, the combined use of an aromatase inhibitor, according to the invention, preferably - exemestane, and a recombinant humanized anti-HER2 antibody, for example the recombinant humanized monoclonal ) antibody anti-HER2 trastuzumab, can be suitable for the treatment of patients with cancers over-expressing the
HER2 protein, for example, for patient with breast cancer, in particular with metastatic breast cancer, over- expressing the HER2 protein.
Suitable modifications and adaptations of a variety of conditions and parameters normally encountered in clinical therapy which are obvious to those skilled in the art are within the scope of this invention.
A pharmaceutically composition containing an aromatase 0 inhibitor and/or an antibody against HER2 can be prepared according to well known techniques to those skilled in the ; art. For instance a pharmaceutical composition containing exemestane can be prepared according to US 4,808,616.
SUBSTITUTE SHEET (RULE 26)
Claims (16)
1. Use of an aromatase inhibitor in the manufacture of a pharmaceutical composition for treatment of an hormone -dependent disorder characterized by the overexpression of HER2, the treatment additionally ) comprising the administration of a composition comprising an antibody against HER2, in amounts effective to produce a superadditive effect.
2. Use, according to claim 1, wherein the disorder is breast, cervical, ovarian and endometrial cancers, and endometriosis.
3. Use, according to claim 2, wherein the disorder is breast cancer.
4. Use, according to claim 1, wherein the aromatase inhibitor is selected from exemestane, aminoglutethimide, roglethimide, pyridoglutethimide, anastrazole, trilostane, testolactone, formestane, atamestane, l-methyl-1,4-androstadiene-3,17-dione (MAD), ketokonazole, fadrozole, 1letrozole, vorozole and anastrozole.
5. Use, according to claim 1, wherein the aromatase inhibitor is exemestane.
6. Use, according to claim 1, wherein the antibody against HER2 is trastuzumab.
7. Use, according to claim 3, wherein the aromatase inhibitor is exemestane and the antibody against HER2 is trastuzumab. SUBSTITUTE SHEET (RULE 26)
8. A method of treating a human being suffering from an hormone-dependent disorder characterized by the overexpression of HER2 comprising administering to . said human being an aromatase inhibitor and an antibody against HER2, in amounts effective to produce oo a superadditive or synergistic therapeutic effect.
9. A method for lowering the side effects caused by antitumor therapy with an aromatase inhibitor in a human being suffering from an hormone-dependent tumor overexpressing HER2, the method comprising administering to said human being a combined preparation comprising an aromatase inhibitor and an antibody against HER2, in amounts effective to produce a superadditive or synergistic antitumor effect. -
10. A method for lowering the side effects caused by antitumor therapy with an antibody against HER2 in a } human being suffering from an hormone-dependent tumor overexpressing HER2, the method comprising administering to said human being a combined preparation comprising an antibody against HER2 and an aromatase inhibitor, in amounts effective to produce a superadditive or synergistic antitumor effect.
11. A method according to claim 8, wherein the disorder is breast, cervical, ovarian and endometrial cancers, and endometriosis. ’ 30
12. A method according to claim 8, wherein the disorder is breast cancer.
13. A method according to claim 8, wherein the aromatase inhibitor is selected from exemestane, aminoglutethimide, roglethimide, pyridoglutethimide, SUBSTITUTE SHEET (RULE 26)
anastrazole, trilostane, testolactone, formestane, atamestane, l1-methyl-1,4-androstadiene-3,17-dione (MAD), ketokonazole, fadrozole, 1letrozole, vorozole and anastrozole.
14. A method according to claim 8, wherein the aromatase inhibitor is exemestane.
15. A method according to claim 8, wherein the antibody against HER2 is trastuzumab.
16. A method according to claim 8, wherein the aromatase inhibitor is exemestane and the antibody against HER2 is trastuzumab. SUBSTITUTE SHEET (RULE 26)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57135500A | 2000-05-15 | 2000-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200209815B true ZA200209815B (en) | 2003-12-03 |
Family
ID=24283360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200209815A ZA200209815B (en) | 2000-05-15 | 2002-12-03 | Aromatase inhibitors and monoclonal anti-HER2 antibodies as antitumors agents. |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1282440A1 (en) |
| JP (1) | JP2003533490A (en) |
| KR (1) | KR20030014223A (en) |
| CN (1) | CN1429118A (en) |
| AU (1) | AU784617B2 (en) |
| BR (1) | BR0110732A (en) |
| CA (1) | CA2409652A1 (en) |
| CZ (1) | CZ20023748A3 (en) |
| EA (1) | EA005931B1 (en) |
| EE (1) | EE200200622A (en) |
| HK (1) | HK1054200A1 (en) |
| HU (1) | HUP0301877A2 (en) |
| IL (1) | IL152389A0 (en) |
| MX (1) | MXPA02011194A (en) |
| NO (1) | NO20025302L (en) |
| NZ (1) | NZ523004A (en) |
| PL (1) | PL360153A1 (en) |
| SK (1) | SK16022002A3 (en) |
| WO (1) | WO2001087334A1 (en) |
| ZA (1) | ZA200209815B (en) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| PL400669A1 (en) | 2000-05-19 | 2012-11-05 | Genentech, Inc. | Genetic probe for detecting a response to ErbB antagonist for improving the likelihood and efficiency of cancer treatment |
| JP2004519490A (en) * | 2001-01-26 | 2004-07-02 | フアルマシア・イタリア・エツセ・ピー・アー | Combination treatment of hormone-dependent abnormalities with exemestane |
| GB2375958B (en) | 2001-04-09 | 2005-03-02 | George Margetts | The use of steroids to lower the levels of cortisol |
| WO2003080835A1 (en) | 2002-03-26 | 2003-10-02 | Zensun (Shanghai) Sci-Tech. Ltd. | Erbb3 based methods and compositions for treating neoplasms |
| PL374431A1 (en) * | 2002-07-01 | 2005-10-17 | Savient Pharmaceuticals, Inc. | Compositions and methods for therapeutic treatment |
| FR2844455B1 (en) * | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | TREATMENT OF PATHOLOGIES EXCLUDING IMMUNE RESPONSE BY OPTIMIZED ANTIBODIES |
| EP1802341A1 (en) * | 2004-07-16 | 2007-07-04 | Pfizer Products Inc. | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody |
| JP2008528486A (en) | 2005-01-21 | 2008-07-31 | ジェネンテック・インコーポレーテッド | Fixed dose of HER antibody |
| RU2404806C2 (en) | 2005-02-23 | 2010-11-27 | Дженентек, Инк. | Extension of time to progression of disease or lifetime of oncologic patients with application of her dimerisation inhibitors |
| JP5449775B2 (en) | 2005-10-19 | 2014-03-19 | チャバフ ピーティーワイ エルティーディー | Reduction of side effects with aromatase inhibitors used to treat breast cancer |
| JP2010520225A (en) | 2007-03-02 | 2010-06-10 | ジェネンテック， インコーポレイテッド | Method for predicting response to HER dimerization inhibitors based on low HER3 expression |
| WO2008154249A2 (en) | 2007-06-08 | 2008-12-18 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| BRPI0812682A2 (en) | 2008-06-16 | 2010-06-22 | Genentech Inc | metastatic breast cancer treatment |
| CN102356092B (en) | 2009-03-20 | 2014-11-05 | 霍夫曼-拉罗奇有限公司 | Bispecific anti-HER antibodies |
| US20120121586A1 (en) | 2009-05-29 | 2012-05-17 | Astrid Kiermaier | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| RU2587619C2 (en) | 2010-02-18 | 2016-06-20 | Дженентек, Инк. | Neuregulin antagonists and use thereof in treating malignant growth |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| WO2012069466A1 (en) | 2010-11-24 | 2012-05-31 | Novartis Ag | Multispecific molecules |
| SG191153A1 (en) | 2010-12-23 | 2013-07-31 | Hoffmann La Roche | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
| CN102068429B (en) * | 2010-12-28 | 2011-12-14 | 西南大学 | Application of fadrozole in inducing transformation of differentiated ovary of tilapia mossambica into functional testis and induction method thereof |
| WO2013025853A1 (en) | 2011-08-17 | 2013-02-21 | Genentech, Inc. | Neuregulin antibodies and uses thereof |
| US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
| EP2785864A2 (en) | 2011-11-30 | 2014-10-08 | F. Hoffmann-La Roche AG | Erbb3 mutations in cancer |
| EP2788500A1 (en) | 2011-12-09 | 2014-10-15 | F.Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
| EP2831115A1 (en) | 2012-03-27 | 2015-02-04 | F. Hoffmann-La Roche AG | Diagnosis and treatments relating to her3 inhibitors |
| US20160038490A1 (en) * | 2012-07-18 | 2016-02-11 | Angion Biomedica Corp. | Compositions and methods for treating dysproliferative diseases |
| CA2889298C (en) | 2012-11-30 | 2024-01-02 | Anton Belousov | Identification of patients in need of pd-l1 inhibitor cotherapy |
| CN113633644A (en) | 2014-10-22 | 2021-11-12 | 哈瓦赫治疗有限公司 | Method for reducing mammographic breast density and/or breast cancer risk |
| SG11201803260PA (en) | 2015-10-22 | 2018-05-30 | Havah Therapeutics Pty Ltd | Methods of reducing mammographic breast density and/or breast cancer risk |
| US20190151346A1 (en) | 2016-05-10 | 2019-05-23 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
| CN107417791B (en) * | 2017-08-17 | 2020-09-22 | 合肥瀚科迈博生物技术有限公司 | Anti-human ErbB2 bispecific antibody, preparation method and application thereof |
| WO2020243777A1 (en) | 2019-06-03 | 2020-12-10 | Havah Therapeutics Pty Ltd | Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
-
2001
- 2001-04-19 EP EP01929585A patent/EP1282440A1/en not_active Withdrawn
- 2001-04-19 EA EA200201213A patent/EA005931B1/en not_active IP Right Cessation
- 2001-04-19 CN CN01809581A patent/CN1429118A/en active Pending
- 2001-04-19 CA CA002409652A patent/CA2409652A1/en not_active Abandoned
- 2001-04-19 SK SK1602-2002A patent/SK16022002A3/en not_active Application Discontinuation
- 2001-04-19 IL IL15238901A patent/IL152389A0/en unknown
- 2001-04-19 BR BR0110732-1A patent/BR0110732A/en not_active IP Right Cessation
- 2001-04-19 MX MXPA02011194A patent/MXPA02011194A/en not_active Application Discontinuation
- 2001-04-19 HU HU0301877A patent/HUP0301877A2/en unknown
- 2001-04-19 WO PCT/EP2001/004468 patent/WO2001087334A1/en active IP Right Grant
- 2001-04-19 KR KR1020027015223A patent/KR20030014223A/en not_active Application Discontinuation
- 2001-04-19 AU AU56309/01A patent/AU784617B2/en not_active Ceased
- 2001-04-19 PL PL36015301A patent/PL360153A1/en not_active Application Discontinuation
- 2001-04-19 CZ CZ20023748A patent/CZ20023748A3/en unknown
- 2001-04-19 EE EEP200200622A patent/EE200200622A/en unknown
- 2001-04-19 JP JP2001583801A patent/JP2003533490A/en not_active Withdrawn
- 2001-04-19 NZ NZ523004A patent/NZ523004A/en unknown
-
2002
- 2002-11-05 NO NO20025302A patent/NO20025302L/en not_active Application Discontinuation
- 2002-12-03 ZA ZA200209815A patent/ZA200209815B/en unknown
-
2003
- 2003-09-11 HK HK03106504.3A patent/HK1054200A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA005931B1 (en) | 2005-08-25 |
| AU784617B2 (en) | 2006-05-18 |
| AU5630901A (en) | 2001-11-26 |
| HUP0301877A2 (en) | 2003-09-29 |
| CN1429118A (en) | 2003-07-09 |
| KR20030014223A (en) | 2003-02-15 |
| NO20025302D0 (en) | 2002-11-05 |
| CA2409652A1 (en) | 2001-11-22 |
| NZ523004A (en) | 2004-09-24 |
| NO20025302L (en) | 2002-11-05 |
| SK16022002A3 (en) | 2003-04-01 |
| MXPA02011194A (en) | 2003-03-10 |
| BR0110732A (en) | 2003-02-04 |
| EE200200622A (en) | 2004-06-15 |
| EA200201213A1 (en) | 2003-04-24 |
| WO2001087334A1 (en) | 2001-11-22 |
| EP1282440A1 (en) | 2003-02-12 |
| HK1054200A1 (en) | 2003-11-21 |
| PL360153A1 (en) | 2004-09-06 |
| IL152389A0 (en) | 2003-05-29 |
| JP2003533490A (en) | 2003-11-11 |
| CZ20023748A3 (en) | 2003-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU784617B2 (en) | Aromatase inhibitors and monoclonal anti-HER2 antibodies as antitumors agents | |
| US20050032759A1 (en) | Antitumor combined therapy | |
| AU2012229147B2 (en) | Use of inhibitors of EGFR-family receptors in the treatment of hormone refractory breast cancers | |
| MXPA06008942A (en) | Anti-epcam immunoglobulins. | |
| JP2023085422A (en) | Combining ErbB-2/ErbB-3 bispecific antibodies with endocrine therapy for breast cancer | |
| EP3463453A1 (en) | Combination of pembrolizumab and abemaciclib for the treatment of cancer | |
| WO2022223006A1 (en) | Use of anti-pd-1 antibody in combination with first-line chemotherapy for treating advanced non-small cell lung cancer | |
| Perry et al. | Trastuzumab | |
| Nozawa et al. | Triple HER2-blockade with lapatinib, trastuzumab, and pertuzumab for treatment of HER2 positive metastatic breast cancer with lymphangitic carcinomatosis: A case study | |
| EA047600B1 (en) | COMBINATION OF A BISPECIFIC ANTIBODY TO ErbB-2/ErbB-3 WITH ENDOCRINE THERAPY FOR BREAST CANCER | |
| Reddy et al. | 2004 Highlights From: The 27th Annual San Antonio Breast Cancer Symposium; San Antonio, TX December 2004 | |
| NZ614427B2 (en) | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers |